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 Abstract   
Objectives: To determine the prevalence and the role of hereditary thrombophilia caused by Factor V Leiden 
(G1691A), prothrombin G20210A or methylenetetrahydrofolate reductase (MTHFR) C677T gene mutations in 
recurrent pregnancy loss.
Material and methods: One hundred and nine patients, who were admitted to the 3rd Obstetrics and Gynecology 
Outpatient Clinic in Goztepe Training and Research Hospital between 2006 and 2008, were included into the study. 
The study group consisted of ﬁ fty-seven patients with a history of 3 miscarriages before 20 weeks of gestation and 
the control group consisted of forty-seven patients with at least one live birth without any history of miscarriage or 
pregnancy complications. The maternal blood was evaluated for Factor V Leiden (G1691A), prothrombin G20210A 
and MTHFR C677T gene mutations.  
Results: No statistically signiﬁ cant diﬀ erence was found between the study and the control groups in terms of the 
prevalence of Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations (p=0.534/
p=0.452/p=0.656, respectively and p<0.05). Furthermore, the prevalence of multiple gene mutations was not 
statistically diﬀ erent between the groups (p=0.375 and p<0.05) either. 
Conclusion: Routine screening for Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene 
mutations in patients with a history of recurrent pregnancy loss is not recommended in Turkish women.
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Introduction
About 50-70% of all conceptions end in miscarriage within 
the fi rst trimester [1]. Up to 40% of the patients suffering 
pregnancy loss are not aware of their pregnancies and can be 
identifi ed only with the beta hCG measurement [2]. Recurrent 
pregnancy loss is defi ned as 3 or more miscarriages within the 
fi rst 20 weeks of gestation. Primary recurrent pregnancy loss 
refers to cases that never had a live birth and secondary recurrent 
pregnancy loss refers to those who did.
The frequency of recurrent pregnancy loss in fertile 
population is 1-2% when those with 3 or more pregnancy losses 
are taken into consideration and 5% when the cases with 2 or more 
pregnancy losses are taken into consideration [3].Using current 
diagnostic methods, the underlying cause can be identifi ed only 
in half of the cases with recurrent pregnancy loss [4].
Thrombophilia is defi ned as congenital or acquired conditions 
that overbalance the coagulation system in the direction of clot 
formation, thereby increasing the risk of thrombosis [5].Hereditary 
thrombophilia is caused by gene mutations that are passed from 
parents to their offspring. Gene mutations that are involved in 
many factors which take part in the coagulation system and other 
factors that maintain the normal fl uidity of the blood in the vessel 
may cause thrombophilia by increasing tendency to thrombosis.
Objectives
In our study we evaluated the relationship between recurrent 
pregnancy loss and Factor V G1691A (Leiden), prothrombin 
G20210A and methylenetetrahydrofolate reductase (MTHFR) 
C677T gene mutations that are associated with maternal 
thrombophilia.
Materials and Methods
One hundred and nine patients, admitted to the 3rd Obstetrics 
and Gynecology Outpatient Clinic in Goztepe Training and 
Research Hospital between 2006 and 2008, were included into 
the study. The study group consisted of fi fty-seven patients 
with a history of 3 consecutive miscarriages before 20 weeks 
of gestation. The control group consisted of forty-seven women 
with at least one live birth and without a history of miscarriage or 
pregnancy complications.
Patient age, age of the spouse, number of abortions, 
abortion week, consanguineous marriage, systemic disorders 
(diabetes mellitus, thyroid disease, chronic liver, kidney or heart 
disease), previous gynecological surgeries and history of venous 
thrombosis were recorded. 
Glucose tolerance test  was performed. All hormone tests 
including follicle stimulating, luteinizing, thyroid stimulating, 
prolactin and progesterone hormones were measured at the 
twenty fi rst day. Pelvic physically exam was performed in all 
patients. Also pelvic structures were evaluated by transvaginal 
sonography for any other genital disorders. The karyotype analysis 
was performed in all patients. IgG and IgM anticardiolipin 
antibodies and lupus anticoagulant were measured in order 
to rule out the antiphospholipid antibody syndrome. We were 
not able to measure IgG antibodies to Beta-2 Glycoprotein 1 
because of technical diffi culties. Factor V Leiden (G1691A) 
mutation, prothrombin G20210A mutation and MTHFR C677T 
mutation were investigated in peripheral blood obtained from the 
patients. Follicular development as well as ultrasound evidence 
of spontaneous ovulation were confi rmed in all patients.
Anticardiolipin IgG antibody returned positive in 2 patients 
who were excluded from the study. One patient was excluded due 
to diabetes mellitus, one patient due to hypothyroidism and one 
patient due to consanguineous marriage. Five cases altogether 
were excluded from the study. There were no patients with an 
impaired glucose tolerance in the study group. None of the cases 
in the study group has lupus anticoagulant and all of the patients 
had ovulatory cycles. The study group consisted solely of women 
with unexplained recurrent pregnancy loss.
Molecular Diagnosis
From the patients in the study group, 2ml of blood was drawn 
into tubes (Vacuette, Austria) coated with K3 Ethylene Diamine 
Tetraacetic Acid (EDTA). 
 Streszczenie   
Cel pracy: Celem pracy była ocena częstości występowania i roli dziedzicznej tromboﬁ lii związanej z mutacją genu 
czynnika V Leiden (G1691A), protrombiny G20210A lub reduktazy methylenotetrahydrofolianowej (MTHFR) C677T 
u pacjentek z nawracającymi poronieniami.
Materiał i metody: Do badania włączono 109 pacjentek, które przyjęto do Poradni Położniczo-Ginekologicznej 
w Goztepe Training and Research Hospital w latach od 2006 do 2008. Grupa badana składała się z 57 pacjentek 
z 3 poronieniami w wywiadzie przed 20 tygodniem ciąży, grupę kontrolną stanowiło 47 pacjentek z przynajmniej 
jednym żywym urodzeniem i bez poronień czy innych komplikacji w wywiadzie. Zbadano krew matek pod kątem 
mutacji genu czynnika V Leiden (G1691A), protrombiny G20210A i MTHFR C677T.
Wyniki: Nie znaleziono istotnej różnicy pomiędzy grupą badaną a kontrolną w odniesieniu do częstości występowania 
mutacji genu czynnika V Leiden (G1691A), protrombiny G20210A i MTHFR C677T (p=0,534/p=0,452/p=0,656 
przy p<0,05 istotnym statystycznie). Co więcej, częstość występowania wielokrotnych mutacji również nie różniła 
się pomiędzy grupami (p=0,375 przy p<0,05).
Wnioski: Nie powinno się rekomendować rutynowego skriningu mutacji genu czynnika V Leiden (G1691A), 
protrombiny G20210A i MTHFR C677T w populacji tureckich kobiet z nawracającymi poronieniami w wywiadzie.
 Słowa kluczowe: czynnik V Leiden / MTHFR / protrombina / trombofi lia / 
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Samples were processed in accordance with the following 
procedure using Genomic DNA from Blood (Macherey-nagel, 
Germany) kit for the isolation of genomic DNA:
Red blood cell lysis.I. 
Setup of the DNA amplifi cation.II. 
DNA binding.III. 
Two-step procedure to wash silica-based membrane.IV. 
Drying silica membrane.V. 
Eluting purifi ed DNA. VI. 
Isolated DNA was stored at -20°C. Mastermix was prepared 
using amplifi cation mix, taq dilution buffer (ViennaLab GmbH, 
Austria) and taq DNA polymerase enzyme (Fermentas Canada 
Inc., Canada) in 0.2ml PCR tube (Greiner Bio-One, Germany). 
Mastermix was added into the PCR tubes and sample DNA 
was amplifi ed in a thermal cycler (Applied Biosystems, USA). 
Finally, assay strips were placed in profi Blot device (Tecan, 
Switzerland) for hybridization. The developed lines on the strips 
were evaluated. 
Statistical Analysis
NCSS 2007&PASS 2008 Statistical Software (Utah, 
USA) package program was used for statistical analyses of the 
study results. Along with descriptive statistics (mean, standard 
deviation, frequency), Student’s t test was used to compare 
quantitative parameters that show normal distribution. Chi-
square test and Fisher’s exact test were used for comparison of 
qualitative parameters. Statistical test results were evaluated by 
using an overall signifi cance level of p<0.05 at 95% confi dence 
interval.
Results
All patients were below 35 years of age (mean age: 26,89±7,32 
years). There was no statistically signifi cant difference between 
the study and the control groups with respect to mean age (p= 
0.665 and p<0.05). Mean age was 30.12±7.32 years in the study 
group and 27.80±6.36 years in the control group.  
Of the cases in the study group, 87.7% were found to be 
negative for Factor V Leiden (G1691A) gene mutation, whereas 
10.5% had heterozygous and 1.8% had homozygous Factor 
V Leiden (G1691A) gene mutation. 59.6% was negative for 
MTHFR C677T gene mutation, and 36.9% had heterozygous and 
3.5% had homozygous MTHFR C677T gene mutation. All cases 
in the study group were negative for prothrombin G20210A gene 
mutation. One case had both, homozygous Factor V Leiden and 
heterozygous MTHFR C677T gene mutations. Three cases had 
both heterozygous Factor V Leiden (G1691A) and heterozygous 
MTHFR C677T gene mutations (Table 1).
Of the cases in the control group, 91.5% were negative for 
Factor V Leiden (G1691A) gene mutation, whereas 8.5% had 
heterozygous gene mutation.55.3% were negative for MTHFR 
C677T gene mutation, whereas 42.6% had heterozygous gene 
mutation and 2.1% had homozygous gene mutation. 97.9% were 
negative for prothrombin G20210A gene mutation whereas 2.1% 
had heterozygous gene mutation. One case in the control group 
had both heterozygous Factor V Leiden (G1691A) gene mutation 
and heterozygous MTHFR C677T gene mutations (Table II).








Negative 50 (87,7%) 34 (59,6%) 57 (100%)
Positive 
Heterozygote 6 (10,5%) 21 (36,9%) -
Homozygote 1 (1,8%) 2 (3,5%) -
TOTAL 57 57 57
Table II. Distribution of the gene mutations in the control group.
Factor V 




Negative 43 (91,5%) 26 (55,3%) 46 (97,9%)
Positive 
Heterozygote 4 (8,5%) 20 (42,6%) 1 (2,1%)
Homozygote - 1 (2,1%) -
TOTAL 47 47 47
The prevalence of Factor V Leiden G1691A gene mutation 
was not signifi cantly different between the groups (p=0.534 and 
p<0.05). The prevalence of Factor V Leiden gene mutation was 
12.3% in the study group and 8.5% in the control group. Factor 
V Leiden gene mutation was associated with 1.505-fold higher 
risk in the study group. However, the risk was not statistically 
signifi cant considering 95% CI being between 0.412-5.491 which 
also covers 1 (Table III). 





p ODDS 95% CI
(n=57) (n=47)
Positive 7 (12,3%) 4 (8,5%)
0,534 1,505 0,412-5,491
Negative 50 (87,7%) 43 (91,5%)
(Chi-Square test was used)
The prevalence of prothrombin G20210A  gene mutations 
was not statistically different between the study and control 
groups (p=0.452 and p<0.05). The risk related with this parameter 
could not be calculated since none of the cases in the study group 
had prothrombin gene mutation (Table IV).
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p ODDS 95% CI
(n=57) (n=47)
Positive 0 (0,0%) 1 (2,1%)
0,452 - -
Negative 57(100,0%) 46 (97,9%)
(Fisher’s Exact test was used)
The prevalence of MTHFR C677T gene mutation was not 
signifi cantly different between the groups (p=0.656 and p<0.05) 
and was 40.4% in the study group and 44.7% in the control group. 
MTHFR C677T gene mutation was associated with 0.838-fold 
higher risk in the study group compared to the control group. 
However, the risk was not statistically signifi cant considering 
95% CI being between 0.383-1.830 which also covers 1 (Table 
V).




p ODDS 95% CI
(n=57) (n=47)
Positive 23 (40,4%) 21 (44,7%)
0,656 0,838 0,383-1,830
Negative 34 (59,6%) 26 (55,3%)
(Chi-Square test was used)
The prevalence of multiple gene mutations was not 
statistically different between the study and the control groups 
(p=0.375 and p<0.05) and was 7.0% in the study group and 2.1% 
in the control group. Multiple gene mutation was associated with 
3,472-fold higher risk. However, the risk was not statistically 
signifi cant considering 95% CI being between 0.375-32,17 which 
covers 1 (Table VI).




p ODDS 95% CI
n (%) n (%)
Positive 4 (7,0%) 1 (2,1%)
0,375 3,472 0,375-32,17Negative 53 (93,0%) 46 (97,9%)
(Fisher’s Exact test was used)
Discussion
Early spontaneous abortion is a serious epidemiological 
problem, which is one of the most common causes of referring 
married couples to genetic counseling [6]. The risk of miscarriage 
decreases as the pregnancy progresses. It is 11.5% when the 
gestational sac is observed but not the embryo; 5% when the 
embryo is measuring 5 mm and fetal heart beat is detectable and 
below 3% at 11 weeks of gestation [7].The risk of spontaneous 
pregnancy loss increases with age, independent from the obstetric 
history of a patient. The patients in the study and control groups 
were below 35 years of age and no signifi cant difference was 
found between the two groups in terms of age (p= 0.665 and 
p<0.05). Among all factors studied until today, genetic, anatomic 
and immunological factors are regarded as the defi nitive causes 
of recurrent pregnancy loss. Alloimmunopathology, hereditary 
thrombophilia, endocrinopathies, infections and environmental 
factors are still under investigation. Even after a detailed 
investigation, defi nitive cause of recurrent pregnancy loss cannot 
be explained in about more than half of the cases.
Thrombophilia refers to a group of congenital or acquired 
coagulation disorders that is characterized by an increased 
tendency to thrombosis. Most genetic mutations predispose to 
thrombosis. Factor V Leiden G1691A, prothrombin G20210A 
and MTHFR C677T gene mutations are the most common 
hereditary abnormalities. Fetal loss related with hereditary 
thrombophilia could be caused by increased thrombosis in the 
placenta vessels, infarctions and utero-placental insuffi ciency. 
Fetal thrombophilia can also play a role in the etiology of fetal 
loss by causing thrombosis in the fetal part of the placenta. Apart 
from being involved in thrombosis, hereditary thrombophilia 
can also lead to fetal loss by interfering with implantation and 
trophoblastic differentiation [8].
There are studies that found no relationship between recurrent 
pregnancy loss and Factor V Leiden G1691A, prothrombin 
G20210A and MTHFR C667T gene mutations. However, there 
are also some studies that suggest a signifi cant relation between 
thrombophilia and recurrent pregnancy loss.
In our study, the prevalence of Factor V Leiden G1691A 
gene mutation was not signifi cantly different between the groups 
(p=0.534 and p<0.05) and was 12.3% in the study group and 
8.5% in the control group (OR: 1.505 [0.412-5.491]). Balasch 
et al. compared 55 patients with more than 2 miscarriages with 
50 patients with no past history of miscarriage. They reported 
no statistically signifi cant difference between the group in terms 
of Factor V Leiden gene mutation [9]. Raziel et al. studied 36 
patients with more than 2 miscarriages compared to 40 patients 
as the control group. They suggested no statistically signifi cant 
difference between the two groups with respect to Factor V 
Leiden gene mutation (OR: 3.42 [0.14-86.71]) [10]. Finan et al. 
found Factor V Leiden G1691A gene mutation in 45 (40.91%) 
out of 110 patients who had a history of recurrent pregnancy loss. 
The prevalence of heterozygous Factor V Leiden gene mutation 
was 16.42% in the control group and they reported a statistically 
signifi cant difference between the two groups [11]. Coutu et al. 
studied 88 cases with 3 or more miscarriages compared to 88 
control cases and the prevalence of homozygous Factor V Leiden 
mutation was 3/88 (3.4%) in the study and 0/88 (0%) in the 
control groups (OR: 7.2 [0.3-142]). They suggested a statistically 
signifi cant difference between the groups for this mutation [12].
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The prevalence of prothrombin G20210A gene mutation 
was not signifi cantly different between the groups in our study 
(p=0.452 and p<0.05). The risk related with this parameter 
could not be calculated since none of the cases in the study 
group had prothrombin gene mutation. Pickering et al. evaluated 
three or more early (< or =12 weeks gestation; n=91), late (>12 
weeks gestation: n=2), or mixed (n=29) consecutive pregnancy 
losses. They compared them to 66 patients without a history of 
miscarriage. The prevalence of heterozygous prothrombin gene 
mutation was found to be similar in both groups (OR: 0.93 [0.16-
5.26]) [13]. Altintas A et al. investigated  the prevalence of Factor 
V Leiden (FV-Leiden) and prothrombin gene mutations (FII 
G20210A) in subjects with a history of early recurrent pregnancy 
loss. The authors found that 2 out of 114 (1.7%) patients in the 
study group (primary aborters) and 3 out of 185 (1.6%) patients 
in the control group were carriers of the FII G20210A mutation 
(1.7 vs. 1.6%, p=0.931). They concluded that the prevalence of 
prothrombin G20210A mutation was not signifi cantly different 
between patients with recurrent pregnancy loss and those in 
the control group [14]. On the other hand, Kupferminc et al. 
evaluated 27 patients with more than 2 miscarriages compared to 
156 control patients and found higher prevalence of heterozygous 
prothrombin G20210A gene mutation in the study group (OR: 5.25 
[1.31-21]) [15]. In another study, 102 patients with two or more 
consecutive abortions and 128 women without miscarriage were 
evaluated for prothrombin G20210A mutation. Heterozygous 
prothrombin G20210A gene mutation occurred more often in 
patients with recurrent spontaneous abortion. This effect was 
signifi cant in the subgroup with abortions happening exclusively 
in the fi rst trimester (6.7% vs. 0.8%, P = 0.027, OR 8.5) [16].
In our study , the prevalence of MTHFR C667T gene mutation 
was not signifi cantly different between the two groups (p=0.656 
and p<0.05). The prevalence of MTHFR C667T gene mutation 
was 40.4% in the study group and 44.7% in the control group 
(OR: 0.838 [0.383-1.830]). A study in Japanese women evaluated 
85 patients with 2 or more miscarriages compared to 76 women 
without a history of miscarriage. No statistically signifi cant 
difference was found between the two groups with respect to 
the prevalence of homozygous MTHFR C667T gene mutation 
[17]. Ren et al. reviewed 26 studies comprising a total of 2120 
cases with recurrent pregnancy loss and 2949 control cases. They 
concluded that MTHFR C677T gene mutation was not a genetic 
risk factor for recurrent pregnancy loss [18]. One Indian study 
evaluated 24 cases with 2 or more miscarriages compared to 24 
control cases. The prevalence of homozygous MTHFR C667T 
gene mutation was found to be 5/24 (13.4%) in the study group 
and 1/24 (4.2%) in the control group. This difference between the 
two groups was statistically signifi cant (p<0.001) [19]. In a study 
by Goodman et al., buccal swabs were obtained for DNA analysis 
from a total of 550 women with a history of recurrent pregnancy 
loss. They found that the prevalence of homozygous MTHFR 
C667T gene mutation was signifi cantly higher in the study group 
as compared to 1956 control cases (p<0.0001) [20]. In our study, 
the prevalence of multiple gene mutations was not signifi cantly 
different between the groups (p=0.375 and p<0.05). The prevalence 
of multiple gene mutations was 7.0% in the study group and 
2.1% in the control group (OR: 3.472 [0.375-32.17]). Sotiriadis 
et al. suggested that no difference existed in the distribution of 
Factor V Leiden (p=1.000 and p<0.05), FII G20210A (p=0.652 
and p<0.05) and MTHFR C677T (p=0.869 and p<0.05) between 
patients with two and three or more miscarriages. Combinations 
of the thrombophilic mutations also did not signifi cantly increase 
the risk of miscarriage [21]. In a study in 2002, Sarig et al. 
found the prevalence of multiple thrombophilic gene mutation 
to be 21% in patients with recurrent pregnancy loss and 5.5% 
in the control group. They reported a statistically signifi cant 
difference between the two groups (p<0.05) [22].On the other 
hand, in a meta-analysis of 31 studies carried out between 1975 
and 2002, Rey et al. recommended an investigation of Factor 
V Leiden and prothrombin gene mutations in patients suffering 
from recurrent early pregnancy loss [23]. In a systematic review 
of 25 studies carried out between 1991 and 2002, Robertson et 
al. evaluated the relationship between thrombophilia and early 
pregnancy loss. They found a statistically signifi cant difference 
between recurrent pregnancy loss and homozygous Factor V 
Leiden gene mutation (OR: 2.71 [1.32-5.58]), heterozygous 
Factor V Leiden gene mutation (OR: 1.68 [1.09-2.58]) and 
heterozygous prothrombin gene mutation (OR: 2.49 [1.24-5.00]). 
They suggested that homozygous Factor V Leiden mutation 
and hyperhomocysteinemia have been associated with a higher 
risk of early pregnancy loss compared to other thrombophilia 
[24]. In another study which is similar to ours, however, it was 
suggested that neither Factor V Leiden nor prothrombin gene 
G20210A are associated with recurrent miscarriage before 10 
weeks of gestation. Therefore, its screening is not recommended 
as an initial approach in Portuguese women with embryonic 
recurrent miscarriage and negative personal thromboembolic 
history [25].
Conclusions
The ACOG Practice Bulletin in “Inherited Thrombophilias in 
Pregnancy” states that inherited thrombophilia testing in women 
who have experienced recurrent fetal loss is not recommended 
because it is unclear whether anticoagulation (blood thinning 
medication) reduces future losses [26]. 
Also, in the view of our results, routine screening for 
thrombophilia is not recommended considering the low incidence 
of hereditary thrombophilia among Turkish women. Randomized 
and controlled studies on larger patient population are needed in 
order to unravel the underlying etiology of recurrent pregnancy 
loss, including particularly hereditary thrombophilia and other 
genetic factors, and to propose standardized treatment protocols.
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XI KONGRES
POLSKIEGO TOWARZYSTWA  MENOPAUZY 
i ANDROPAUZY
8 – 9 lutego  2013 r.
 Krynica-Zdrój,  Hotel Prezydent***** 
I   K O M U N I K A T
Szanowni Państwo, Koleżanki i Koledzy
W dniach 8-9 lutego przyszłego roku odbędzie się w Krynicy Górskiej 
IX Kongres Polskiego Towarzystwa Menopauzy i Andropauzy. Kongres 
poświęcony będzie najnowszym trendom w diagnostyce i terapii 
problemów  zdrowotnych okresu menopauzy i andropauzy. 
T e m a t y  w i o d ą c e  Z j a z d u  t o :
• Standardy HTZ w 12 lat po WHI
• Najnowsze trendy w medycynie Anti-Aging – wskazówki dla 
praktyka 
• Problemy uroginekologiczne okresu menopauzy
• Leczenie operacyjne pacjentki pomenopauzalnej – odrębności 
postępowania okołooperacyjnego
• Problemy psychosomatyczne po menopauzie (depresja, 
spadek libido, zaburzenia snu) – jak leczyć?
• Jak skutecznie zapobiegać zaburzeniom biocenozy pochwy po 
menopauzie?
• Antykoncepcja w okresie przejścia menopauzalnego – 
bezpieczeństwo, tolerancja, korzyści pozaantykoncepcyjne
• Szkody jatrogenne hormonoterapii – jak zminimalizować 
ryzyko?
• Czy będziemy coraz rzadziej operować mięśniaki macicy?
• Suplementy diety po menopauzie – komu, co i w jakim celu?
Ambicją organizatorów jest aby połączyć najwyższej próby walory 
naukowe i szkoleniowe Zjazdu z możliwością relaksu w pięknej Krynicy. 
Zaproszenie do udziału w Kongresie przyjęło liczne grono wybitnych 
wykładowców. 
Formularz zgłoszenia uczestnictwa i szczegóły dotyczące Kongresu 
znajdziecie Państwo na stronie 
www.konferencje.magan.pl
D o  z o b a c z e n i a  w  l u t y m  2 0 1 3  w  K r y n i c y !       
 
 Prof. zw. dr hab. Tomasz Paszkowski
 Prezes PTMA
K O M U N I K A T
